Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma
Kyriakou, C.; Thomson, K.; D'Sa, S.; Flory, A.; Hanslip, J.; Goldstone, A.H.; Yong, K.L.
British Journal of Haematology 129(6): 763-770
2005
ISSN/ISBN: 0007-1048 PMID: 15953002 DOI: 10.1111/j.1365-2141.2005.05521.x
Accession: 012276929
The feasibility and efficacy of a triple regimen of oral weekly cyclophosphamide, monthly pulsed dexamethasone and low-dose Thalidomide (CDT) was studied in 52 patients with relapsed or refractory multiple myeloma (MM). All 52 patients were evaluable for response with a median follow up of 18 (4-29) months.
PDF emailed within 0-6 h: $19.90
Related References
Kyriakou, C.A.; D'sa, S.P.; Flory, A.; Hanslip, J.; Peggs, K.S.; Yong, K.L. 2003: Cyclophosphamide, dexamethasone and thalidomide is a well tolerated and effective regimen in advanced relapsed/refractory myeloma Blood 102(11): 386bGarcía-Sanz, R.; González-Porras, J.R.; Hernández, J.M.; Polo-Zarzuela, M.; Sureda, A.; Barrenetxea, C.; Palomera, L.; López, R.; Grande-García, C.; Alegre, A.; Vargas-Pabón, M.; Gutiérrez, O.N.; Rodríguez, J.A.; San Miguel, J.F. 2004: The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma Leukemia 18(4): 856-863
Kropff, M.H.; Lang, N.; Bisping, G.; Dominé, N.; Innig, G.; Hentrich, M.; Mitterer, M.; Südhoff, T.; Fenk, R.; Straka, C.; Heinecke, A.; Koch, O.M.; Ostermann, H.; Berdel, W.E.; Kienast, J. 2003: Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma British Journal of Haematology 122(4): 607-616
D.R.imondo, F.; Pennisi, A.; Buglio, D.; Fiumara, P.; Palumbo, G.A.; Giustolisi, R. 2003: Addition of low dose cyclophosphamide to the combination of Thalidomide and Dexamethasone in patients with relapsed/refractory multiple myeloma Blood 102(11): 385b
Ciolli, S.; Leoni, F.; Gigli, F.; Rigacci, L.; Bosi, A. 2006: Low dose Velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma patients Leukemia and Lymphoma 47(1): 171-173
Gao, W.; An, N.; Chen, S.-l. 2006: The effect of cyclophosphamide, thalidomide and dexamethasone combination therapy in relapsed/refractory multiple myeloma Zhonghua Nei Ke Za Zhi 45(3): 221-222
Sidra, G.M.; Byrne, J.L.; Myers, B.; Mitchell, D.C.; Russell, N.H. 2002: Combination therapy with Thalidomide, Cyclophosphamide and Dexamethasone for relapsed and primary refractory multiple myeloma British Journal of Haematology 117(Suppl 1): 64
Kim, Y.-K.; Sohn, S.-K.; Lee, J.-H.; Yang, D.-H.; Moon, J.-H.; Ahn, J.-S.; Kim, H.-J.; Lee, J.-J. 2010: Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase Ii study Annals of Hematology 89(5): 475-482
García-Sanz, Rón.; González-Fraile, M.Isabel.; Sierra, M.; López, C.; González, M.; San Miguel, Jús.Fernando. 2002: The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma Hematology Journal: the Official Journal of the European Haematology Association 3(1): 43-48
Mele, G.; Giannotta, A.; Pinna, S.; Loseto, G.; Coppi, M.R.; Brocca, C.M.; Melpignano, A.; Quarta, G. 2010: Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide Leukemia and Lymphoma 51(5): 937-940
Waterman, G.N.; Yellin, O.; Swift, R.A.; Mapes, R.; Eades, B.; Ackerman, E.; Berenson, J.R. 2011: A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma Annals of Hematology 90(2): 193-200
Dimopoulos, M.A.; Hamilos, G.; Zomas, A.; Gika, D.; Efstathiou, E.; Grigoraki, V.; Poziopoulos, C.; Xilouri, I.; Zorzou, M.P.; Anagnostopoulos, N.; Anagnostopoulos, A. 2004: Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma Hematology Journal: the Official Journal of the European Haematology Association 5(2): 112-117
Hinsley, S.; Walker, K.; Sherratt, D.; Bailey, L.; Reed, S.; Flanagan, L.; McKee, S.; Brudenell Straw, F.; Dawkins, B.; Meads, D.; Auner, H.W.; Kaiser, M.F.; Cook, M.; Brown, S.; Cook, G. 2020: The MUK eight protocol: a randomised phase Ii trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor Trials 21(1): 826
Giles, F.J.; Wickham, N.R.; Rapoport, B.L.; Fong, W.; Somio, G.; Fuerst, M.P.; Kusuanco, D.A.; Franco, M.M.; Fischer, D.A.; Hughlett, C.E.; Lim, S.W. 1996: Cyclophosphamide, etoposide, vincristine, adriamycin and dexamethasone /rGM-CSF is an effective regimen in refractory or relapsed multiple myeloma Blood 88(10 Suppl 1 Part 1-2): 219B
Togano, T.; Andoh, S.; Komuro, M.; Mitsui, Y.; Itoi, S.; Hirai, R.; Nakamura, M.; Tanimura, A.; Sekine, R.; Takeshita, M.; Miwa, A.; Hagiwara, S. 2022: Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a Salvage and Bridging Regimen before Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma Internal Medicine 61(22): 3329-3334
Terpos, E.; Kastritis, E.; Roussou, M.; Heath, D.; Christoulas, D.; Anagnostopoulos, N.; Eleftherakis-Papaiakovou, E.; Tsionos, K.; Croucher, P.; Dimopoulos, M.A. 2008: The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis Leukemia 22(12): 2247-2256
Dimopoulos, M.A.; Anagnostopoulos, A.; Hamilos, G.; Zomas, A.; Efstathiou, E.; Grigoraki, V.; Poziopoulos, C.; Gika, D.; Xilouri, I.; Zorzou, M.P.; Anagnostopoulos, N. 2003: Pulsed cyclophosphamide, thalidomide and dexamethasone Long term follow-up of an oral regimen for previously treated patients with multiple myeloma Blood 102(11): 148a-149a
Trieu, Y.; Trudel, S.; Pond, G.R.; Mikhael, J.; Jaksic, W.; Reece, D.E.; Chen, C.I.; Stewart, A.K. 2005: Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation Mayo Clinic Proceedings 80(12): 1578-1582
Sidra, G.M.; Russell, N.; Byrne, J.; Myers, B.; Mitchell, D. 2002: Combination Therapy with Thalidomide, Cyclophosphamide and Dexamethasone for VAD-Refractory and Relapsed Myeloma Blood 100(11): Abstract No. 5125
Dmoszynska, A.; Walter-Croneck, A.; Hus, I.; Grzasko, N.; Manko, J.; Jedrzejczak, W.Wiktor.; Charlinski, G.; Usnarska-Zubkiewicz, L.; Skotnicki, A.; Wolska-Smolen, T.; Piszcz, J.; Kloczko, J. 2010: The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma--a report by the Polish Myeloma Study Group Leukemia Research 34(10): 1330-1335